AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
April 18, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1002 is being studied for the treatment of adults with non-ischemic...
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
April 16, 2024 08:03 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
AskBio Names Mansuo Shannon Chief Scientific Officer
April 09, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyCo-Founder and former Chief...
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
February 13, 2024 08:10 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany and Research Triangle Park, NC, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1002 is an investigational gene therapy for the treatment of adults with...
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)
January 05, 2024 08:11 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer...
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
January 28, 2021 09:20 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company and wholly owned...
Gene Therapy Leader Katherine High Joins AskBio as President, Therapeutics
January 12, 2021 10:37 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company and wholly owned...
AskBio CSO Jude Samulski Named 2020 Business Person of the Year by Triangle Business Journal
December 11, 2020 09:07 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
November 19, 2020 08:00 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the...
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia
October 20, 2020 08:00 ET
|
Asklepios BioPharmaceutical, Inc.
WATERTOWN, Mass., and Research Triangle Park, N.C., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the...